Neoadjuvant Vemurafenib for Borderline Resectable Metastatic Melanoma to Liver: A Case Report

Yifei Sun, James Beattie, H

Abstract

Vemurafenib is a selective inhibitor of mutated B-Raf protein, which is found in 60% of metastatic melanoma. Neoadjuvant Vemurafenib for patient with metastatic melanoma, to decrease tumor size prior to surgical resection has been reported in patients with metastatic melanoma to the brain and lymph nodes. We present a case of neoadjuvant Vemurafenib in a patient with large borderline resectable metastatic melanoma to the liver.

Relevant Publications in Journal of Carcinogenesis & Mutagenesis